WW International (WW)
(Delayed Data from NSDQ)
$1.37 USD
-0.05 (-3.52%)
Updated Oct 17, 2024 04:00 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Price, Consensus and EPS Surprise
WW 1.37 -0.05(-3.52%)
Will WW be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for WW based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for WW
WW International (WW) Reports Q2 Loss, Lags Revenue Estimates
Norwegian Cruise Line (NCLH) Tops Q2 Earnings and Revenue Estimates
WW: What are Zacks experts saying now?
Zacks Private Portfolio Services
Analysts Estimate WW International (WW) to Report a Decline in Earnings: What to Look Out for
Xponential Fitness (XPOF) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Planet Fitness (PLNT) Q4 Earnings and Revenues Beat Estimates
Other News for WW
12 Consumer Discretionary Stocks Moving In Tuesday's Pre-Market Session
WeightWatchers and Hims & Hers Health Stocks Surge on FDA Decision
FDA to reconsider barring compounded versions of weight loss drug, Reuters says
WW International (WW) Stock Rises on Potential Reconsideration of Weight Loss Drug Ban
FDA to review removal of Eli Lilly weight loss drug from shortage list